PURPOSE: Radiation dose intensification improves outcome in men with high-risk prostate cancer (HR-PCa). A prospective trial was conducted to determine safety, feasibility, and maximal tolerated dose of multilevel magnetic resonance imaging (MRI)-based 5-fraction SABR in patients with HR-PCa. METHODS AND MATERIALS: This phase I clinical trial enrolled patients with HR-PCa with grade group ≥4, prostate-specific antigen (PSA) ≥20 ng/mL, or radiographic ≥T3, and well-defined prostatic lesions on multiparametric MRI (mpMRI) into 4 dose-escalation cohorts. The initial cohort received 47.5 Gy to the prostate, 50 Gy to mpMRI-defined intraprostatic lesion(s), and 22.5 Gy to pelvic lymph nodes in 5 fractions. Radiation doses were escalated for pelvic nodes to 25 Gy and mpMRI lesion(s) to 52.5 Gy and then 55 Gy. Escalation was performed sequentially according to rule-based trial design with 7 to 15 patients per cohort and a 90-day observation period. All men received peri-rectal hydrogel spacer, intraprostatic fiducial placement, and 2 years of androgen deprivation. The primary endpoint was maximal tolerated dose according to a 90-day acute dose-limiting toxicity (DLT) rate <33%. DLT was defined as National Cancer Institute Common Toxicity Criteria for Adverse Events ≥grade 3 treatment-related toxicity. Secondary outcomes included acute and delayed gastrointestinal (GI)/genitourinary (GU) toxicity graded with Common Toxicity Criteria for Adverse Events. RESULTS: Fifty-five of the 62 enrolled patients were included in the analysis. Dose was escalated through all 4 cohorts without observing any DLTs. Median overall follow-up was 18 months, with a median follow-up of 42, 24, 12, and 7.5 months for cohorts 1 to 4 respectively. Acute and late grade 2 GU toxicities were 25% and 20%, while GI were 13% and 7%, respectively. Late grade 3 GU and GI toxicities were 2% and 0%, respectively. CONCLUSIONS: SABR dose for HR-PCa was safely escalated with multilevel dose painting of 47.5 Gy to prostate, 55 Gy to mpMRI-defined intraprostatic lesions, and 25 Gy to pelvic nodal region in 5 fractions. Longer and ongoing follow-up will be required to assess late toxicity.
PURPOSE: Radiation dose intensification improves outcome in men with high-risk prostate cancer (HR-PCa). A prospective trial was conducted to determine safety, feasibility, and maximal tolerated dose of multilevel magnetic resonance imaging (MRI)-based 5-fraction SABR in patients with HR-PCa. METHODS AND MATERIALS: This phase I clinical trial enrolled patients with HR-PCa with grade group ≥4, prostate-specific antigen (PSA) ≥20 ng/mL, or radiographic ≥T3, and well-defined prostatic lesions on multiparametric MRI (mpMRI) into 4 dose-escalation cohorts. The initial cohort received 47.5 Gy to the prostate, 50 Gy to mpMRI-defined intraprostatic lesion(s), and 22.5 Gy to pelvic lymph nodes in 5 fractions. Radiation doses were escalated for pelvic nodes to 25 Gy and mpMRI lesion(s) to 52.5 Gy and then 55 Gy. Escalation was performed sequentially according to rule-based trial design with 7 to 15 patients per cohort and a 90-day observation period. All men received peri-rectal hydrogel spacer, intraprostatic fiducial placement, and 2 years of androgen deprivation. The primary endpoint was maximal tolerated dose according to a 90-day acute dose-limiting toxicity (DLT) rate <33%. DLT was defined as National Cancer Institute Common Toxicity Criteria for Adverse Events ≥grade 3 treatment-related toxicity. Secondary outcomes included acute and delayed gastrointestinal (GI)/genitourinary (GU) toxicity graded with Common Toxicity Criteria for Adverse Events. RESULTS: Fifty-five of the 62 enrolled patients were included in the analysis. Dose was escalated through all 4 cohorts without observing any DLTs. Median overall follow-up was 18 months, with a median follow-up of 42, 24, 12, and 7.5 months for cohorts 1 to 4 respectively. Acute and late grade 2 GU toxicities were 25% and 20%, while GI were 13% and 7%, respectively. Late grade 3 GU and GI toxicities were 2% and 0%, respectively. CONCLUSIONS: SABR dose for HR-PCa was safely escalated with multilevel dose painting of 47.5 Gy to prostate, 55 Gy to mpMRI-defined intraprostatic lesions, and 25 Gy to pelvic nodal region in 5 fractions. Longer and ongoing follow-up will be required to assess late toxicity.
Authors: Anders Widmark; Adalsteinn Gunnlaugsson; Lars Beckman; Camilla Thellenberg-Karlsson; Morten Hoyer; Magnus Lagerlund; Jon Kindblom; Claes Ginman; Bengt Johansson; Kirsten Björnlinger; Mihajl Seke; Måns Agrup; Per Fransson; Björn Tavelin; David Norman; Björn Zackrisson; Harald Anderson; Elisabeth Kjellén; Lars Franzén; Per Nilsson Journal: Lancet Date: 2019-06-18 Impact factor: 79.321
Authors: Hiromichi Ishiyama; Takahiro Hirayama; Pavan Jhaveri; Takefumi Satoh; Arnold C Paulino; Bo Xu; Edward Brian Butler; Bin S Teh Journal: Am J Clin Oncol Date: 2014-06 Impact factor: 2.339
Authors: D W Nathan Kim; L Chinsoo Cho; Christopher Straka; Alana Christie; Yair Lotan; David Pistenmaa; Brian D Kavanagh; Akash Nanda; Patrick Kueplian; Jeffrey Brindle; Susan Cooley; Alida Perkins; David Raben; Xian-Jin Xie; Robert D Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-01 Impact factor: 7.038
Authors: Kiri A Sandler; Ryan R Cook; Jay P Ciezki; Ashley E Ross; Mark M Pomerantz; Paul L Nguyen; Talha Shaikh; Phuoc T Tran; Richard G Stock; Gregory S Merrick; David Jeffrey Demanes; Daniel E Spratt; Eyad I Abu-Isa; Trude B Wedde; Wolfgang Lilleby; Daniel J Krauss; Grace K Shaw; Ridwan Alam; Chandana A Reddy; Daniel Y Song; Eric A Klein; Andrew J Stephenson; Jeffrey J Tosoian; John V Hegde; Sun Mi Yoo; Ryan Fiano; Anthony V D'Amico; Nicholas G Nickols; William J Aronson; Ahmad Sadeghi; Stephen C Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Robert E Reiter; Jonathan W Said; Michael L Steinberg; Eric M Horwitz; Patrick A Kupelian; Christopher R King; Amar U Kishan Journal: Eur Urol Date: 2019-04-13 Impact factor: 20.096
Authors: Michael R Folkert; Michael J Zelefsky; Raquibul Hannan; Neil B Desai; Yair Lotan; Aaron M Laine; D W Nathan Kim; Sarah Hardee Neufeld; Brad Hornberger; Marisa A Kollmeier; Sean McBride; Chul Ahn; Claus Roehrborn; Robert D Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2021-03-19 Impact factor: 7.038
Authors: Raquibul Hannan; Vasu Tumati; Xian-Jin Xie; L Chinsoo Cho; Brian D Kavanagh; Jeffrey Brindle; David Raben; Akash Nanda; Susan Cooley; D W Nathan Kim; David Pistenmaa; Yair Lotan; Robert Timmerman Journal: Eur J Cancer Date: 2016-03-29 Impact factor: 9.162
Authors: Larry E Miller; Jason A Efstathiou; Samir K Bhattacharyya; Heather A Payne; Emily Woodward; Michael Pinkawa Journal: JAMA Netw Open Date: 2020-06-01
Authors: Linda G W Kerkmeijer; Veerle H Groen; Floris J Pos; Karin Haustermans; Evelyn M Monninkhof; Robert Jan Smeenk; Martina Kunze-Busch; Johannes C J de Boer; Jochem van der Voort van Zijp; Marco van Vulpen; Cédric Draulans; Laura van den Bergh; Sofie Isebaert; Uulke A van der Heide Journal: J Clin Oncol Date: 2021-01-20 Impact factor: 44.544